Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Gleevec And Arsenic Trioxide

Research Leaders

5 sponsors active, led by New Mexico Cancer Research Alliance

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Recruiting2
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT03555851Recruiting

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

NCT02560883RecruitingPrimary

Hairy Cell Leukemia Patient Data Registry

NCT00250042Phase 2CompletedPrimary

A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec

Showing all 3 trials

Research Network

Common Treatments

  • Gleevec And Arsenic Trioxide1
  • Cyclophosphamide1
  • Specimen Collection1

Active Sponsors

  • New Mexico Cancer Research Alliance1
  • Hairy Cell Leukemia Foundation1
  • Wake Forest University Health Sciences1
  • Ohio State University Comprehensive Cancer Center1
  • Atrium Health Levine Cancer Institute1

Top Investigators

Related Conditions

  • Leukemia Not Otherwise Specified1
  • Cancer1

Activity Timeline